EverGlade Consulting, a national consulting firm, has helped GeoVax Labs, Inc successfully secure up to $45 million in funding to advance the development of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine through the Rapid Response Portfolio Vehicle (RRPV) consortium funded by the Biomedical Advanced Research and Development Authority (“BARDA”).
EverGlade Consulting Helps GeoVax Secure up to $45 Million in BARDA Funding
